低剂量伐昔洛韦治疗带状疱疹眼病:带状疱疹眼病随机临床试验
ZEDS随机临床试验在95个中心纳入527例免疫功能正常、有带状疱疹眼病皮疹史且1年内有活动性角膜炎或虹膜炎的成人,随机接受12个月双盲每日伐昔洛韦1000 mg或安慰剂。12个月主要终点无显著差异(HR 0.77,95%CI 0.56-1.05,P=0.09),但18个月次要终点显示伐昔洛韦优于安慰剂(HR 0.73,95%CI 0.55-0.97,P=0.03),且12和18个月多个其他次要终点减少。
要点
- 12个月主要终点伐昔洛韦组33% vs 安慰剂组28%(HR 0.77,95%CI 0.56-1.05,P=0.09),无显著差异。
- 18个月次要终点伐昔洛韦组32% vs 安慰剂组40%(HR 0.73,95%CI 0.55-0.97,P=0.03)。
- 12和18个月多个其他次要终点减少(12个月HR 0.70,95%CI 0.52-0.95,P=0.02;18个月HR 0.72,95%CI 0.55-0.95,P=0.02)。
核心结论
- 主要终点未显示抑制性伐昔洛韦治疗的获益,但次要研究终点在18个月时显示治疗优效,且12和18个月时多个角膜炎或虹膜炎发作次数减少。
- 这些结果支持考虑对带状疱疹眼病患者进行1年抑制性伐昔洛韦治疗。
研究设计与样本
- ZEDS为随机临床试验,于2017年11月至2024年6月在95个中心开展。
- 纳入免疫功能正常、非妊娠成人,有带状疱疹眼病皮疹史、1年内记录到活动性角膜炎或虹膜炎,且估算肾小球滤过率≥45 mL/min/1.73 m2。
- 共527例参与者随机分组(伐昔洛韦组266例,安慰剂组261例),按发病年龄(<60岁 vs ≥60岁)和病程(<6个月 vs ≥6个月)分为4层。
- 干预为12个月双盲每日伐昔洛韦1000 mg或安慰剂;481例完成12个月,460例完成18个月;按意向性分析。
主要发现
- 12个月主要终点(新发或加重基质角膜炎、内皮角膜炎、虹膜炎或树枝状上皮角膜炎)伐昔洛韦组28%(74例)vs 安慰剂组33%(86例)(HR 0.77,调整95%CI 0.56-1.05,P=0.09)。
- 18个月次要终点伐昔洛韦组32%(86例)vs 安慰剂组40%(104例)(HR 0.73,调整95%CI 0.55-0.97,P=0.03)。
- 12个月多个其他次要终点减少(HR 0.70,95%CI 0.52-0.95,P=0.02),18个月亦减少(HR 0.72,95%CI 0.55-0.95,P=0.02)。
关键数值与推荐
- 12个月主要终点HR 0.77(调整95%CI 0.56-1.05,P=0.09)。
- 18个月次要终点HR 0.73(调整95%CI 0.55-0.97,P=0.03)。
- 12个月多个其他次要终点HR 0.70(95%CI 0.52-0.95,P=0.02);18个月HR 0.72(95%CI 0.55-0.95,P=0.02)。
临床怎么用
- 作者认为这些结果支持考虑对带状疱疹眼病患者进行1年抑制性伐昔洛韦治疗。
局限性
- 12个月主要终点未显示获益(HR 0.77,调整95%CI 0.56-1.05,P=0.09)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: High-quality evidence regarding suppressive valacyclovir treatment in herpes zoster ophthalmicus (HZO) is necessary to guide care. OBJECTIVE: To determine whether suppressive valacyclovir compared with placebo delays the occurrence of new or worsening stromal keratitis (SK), endothelial keratitis (EK), iritis, or dendriform epithelial keratitis (DEK) during 12 months of treatment and if treatment benefit persisted at 18 months (secondary end point). DESIGN, SETTING, AND PARTICIPANTS: The Zoster Eye Disease Study (ZEDS) was a randomized clinical trial conducted in 95 sites from November 2017 to June 2024. Immunocompetent, nonpregnant adults with a history of an HZO rash, documented active keratitis or iritis within 1 year, and an estimated glomerular filtration rate of 45 mL/min/1.73 m2 or greater were eligible. After determined to be eligible, participants were randomized in 4 strata: age at onset (<60 years vs ≥60 years) and disease duration (<6 months vs ≥6 months). INTERVENTIONS: A total of 12 months of double-masked daily valacyclovir, 1000 mg, or placebo. MAIN OUTCOMES AND MEASURES: The primary outcome was time to first occurrence within 12 months of new or worsening SK, EK, iritis, or DEK. RESULTS: A total of 527 participants (median [IQR] age, 60 [50-68] years; 266 female [50.5%]; 266 in the valacyclovir group; 261 in the placebo group) were randomized in 4 strata; 481 completed 12 months, and 460 completed 18 months. Data were analyzed by intention to treat. At 12 months, primary end points occurred in 86 participants (33%) assigned to placebo and 74 (28%) assigned to valacyclovir, and at 18 months in 104 participants (40%) assigned to placebo and 86 (32%) assigned to valacyclovir. The hazard ratio (HR) of the primary end point at 12 months was 0.77 for participants taking valacyclovir vs placebo (HR, 0.77; adjusted 95% CI, 0.56-1.05; P = .09) and 0.73 at the secondary end point at 18 months (HR, 0.73; adjusted 95% CI, 0.55-0.97; P = .03). There was a reduction of multiple other secondary end points at 12 months (HR, 0.70; 95% CI, 0.52-0.95; P = .02) and 18 months (HR, 0.72; 95% CI, 0.55-0.95; P = .02). CONCLUSIONS AND RELEVANCE: Although the primary outcome did not show a benefit of suppressive valacyclovir treatment, secondary study outcomes showed treatment superiority at the 18-month end point and reduced number of multiple episodes of keratitis or iritis at both 12 and 18 months. These results support consideration of 1 year of suppressive valacyclovir treatment for HZO. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03134196.
引用
- Cohen EJ, Troxel AB, Liu M, et al. Low-Dose Valacyclovir in Herpes Zoster Ophthalmicus: The Zoster Eye Disease Randomized Clinical Trial. JAMA Ophthalmol. 2025. PMID: 40048183. doi:10.1001/jamaophthalmol.2024.6114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。